WO2023175069A1 - Bibliothèque d'appariement de régions constantes de tcr pour tcr pramevld - Google Patents

Bibliothèque d'appariement de régions constantes de tcr pour tcr pramevld Download PDF

Info

Publication number
WO2023175069A1
WO2023175069A1 PCT/EP2023/056737 EP2023056737W WO2023175069A1 WO 2023175069 A1 WO2023175069 A1 WO 2023175069A1 EP 2023056737 W EP2023056737 W EP 2023056737W WO 2023175069 A1 WO2023175069 A1 WO 2023175069A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
tcr
seq
group
acid sequence
Prior art date
Application number
PCT/EP2023/056737
Other languages
English (en)
Inventor
Slavoljub Milosevic
Adriana TURQUETI NEVES
Andreas ACS
Justyna OGONEK
Original Assignee
Medigene Immunotherapies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Immunotherapies Gmbh filed Critical Medigene Immunotherapies Gmbh
Publication of WO2023175069A1 publication Critical patent/WO2023175069A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • the present invention relates library of synthetic polynucleotides encoding TCR alpha chain constant regions and TCR beta chain constant regions of a TCR capable of binding to a PRAME peptide having the sequence VLDGLDVLL (SEQ ID NO: 3) for enhanced pairing of recombinant TCR alpha and TCR beta chains and/or enhanced surface expression of recombinant TCRs.
  • the invention further refers to corresponding vector libraries, TCR libraries, cell libraries and methods for isolating TCRs with enhanced TCR alpha and TCR beta chain pairing using said libraries and TCRs isolated from said libraries as well as the medical use thereof.
  • T lymphocytes are part of the adaptive immune response and originate from hematopoietic stem cells located in the bone marrow. T lymphocytes express a unique antigen binding receptor on their membrane, the T cell receptor (TCR), which recognizes antigens in association with major histocompatibility complex (MHC) molecules.
  • TCR T cell receptor
  • T cells With their central role in the immune system, T cells typically provide protection from pathogens or malignant cells. Each T cell expresses a single form of a T cell receptor, a structure which is used by the T cell to recognize infected or altered cells.
  • the concept of immunotherapy is based on the specificity of the adaptive immune response for the recognition and elimination of pathogens as well as tumor cells.
  • the aim of a successful immunotherapy is the manipulation or reprogramming of the patient’s immune response in order to specifically target pathogen-infected cells or tumor cells for destruction by the immune system.
  • DJB:ADW Therapeutic approaches used to reprogram the immune system in the treatment of infectious diseases and cancer include active immunotherapy comprising the use of vaccination strategies, including dendritic cell (DC) vaccines, as well as passive immunotherapy comprising the application of specific antibodies or genetically engineered lymphocytes or the adoptive transfer of T cells specifically recognizing target antigens displayed by pathogen-infected cells or cancers.
  • active immunotherapy comprising the use of vaccination strategies, including dendritic cell (DC) vaccines
  • passive immunotherapy comprising the application of specific antibodies or genetically engineered lymphocytes or the adoptive transfer of T cells specifically recognizing target antigens displayed by pathogen-infected cells or cancers.
  • TILs tumor-infiltrating lymphocytes
  • These genetically engineered T cells can for example be created by transduction of autologous T cells with the a and [3 chains of target-specific TCRs, i.e. with recombinant TCRs.
  • target-specific TCRs i.e. with recombinant TCRs.
  • virus-specific T cells for example to combat Epstein-Barr-Virus- and Cytomegalovirus-driven infections in immunocompromised individuals. This is a pathway that could also be pursued for treatment of COVID-19 patients in dire situations.
  • T cells and their corresponding TCRs can be obtained by culturing autologous T cells and autologous DCs expressing the human leukocyte antigens (HLAs) of choice and loaded with foreign antigens, such as those expressed by pathogenic viruses in infected cells.
  • HLAs human leukocyte antigens
  • T cell cultivation and expansion of individual T cell clones is laborious and requires repeated rounds of re-stimulation, it is an advantage to rapidly acquire the sequences of the TCRs at an early time point in order to allow their rapid characterization by introducing them into recipient peripheral blood lymphocytecontaining T cells. This allows the characterization of the TCRs regarding antigen specificity, peptide/MHC-avidity and functionality before they are selected for further use in therapeutic applications in patients.
  • TCR-T immunotherapy both safety and efficacy of TCR-T immunotherapy need further to be improved.
  • strong surface expression of the TCR is vital.
  • a prerequisite for high expression of the TCR on the cell surface is the correct pairing of the TCR alpha and TCR beta chains.
  • mispairing of the recombinant TCR chains with the endogenous TCR chains must be avoided.
  • WO201 7/216324 describes TCRs capable of binding to a preferentially expressed antigen in melanoma (PRAME) peptide having the sequence VLDGLDVLL (SEQ ID NO: 3), also denoted PRAMEVLD herein, or its MHC-bound form.
  • PRAME preferentially expressed antigen in melanoma
  • the present invention provides libraries and methods for improving the pairing of the recombinant TCR alpha and TCR beta chains of TCRs targeting PRAMEVLD. Thereby the surface expression of the transgenic TCR chains can be increased. The inventors could show that surprisingly these strategies lead to TCRs with increased functional avidity.
  • TCR-T immunotherapy when recombinant TCRs are expressed in T cells carrying the endogenous TCR, the mispairing of recombinant TCR chains with endogenous TCR chains can thereby be reduced.
  • the inventors identified specific positions in the constant regions of the TCR alpha and TCR beta chain that impact binding of both chains and collated a library of tailored amino acid substitutions in the constant regions of the TCR alpha and TCR beta chains, which can be introduced to potentially elicit improved binding between the chains.
  • the inventors found that the improved binding by the modified chains resulted in enhanced TCR surface expression and function leading to TCR-Ts expressing such TCRs with improved in vitro efficacy in target cell recognition.
  • a first aspect of the invention relates to a library of synthetic polynucleotides encoding TCR alpha chains and TCR beta chains of a TCR capable of binding to a PRAME peptide having the sequence VLDGLDVLL (SEQ ID NO: 3), comprising
  • TCR alpha chain constant regions which are selected from the group of TCR alpha constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO: 1 ;
  • TCR alpha chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 4, a CDR2 having the amino acid sequence of SEQ ID NO: 5 and a CDR3 having the amino acid sequence of SEQ ID NO: 6;
  • TCR beta chain constant regions which are selected from the group of TCR beta constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO: 15;or
  • TCR beta chain constant regions which are selected from the group of TCR beta constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO: 16; b) TCR beta chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 7, a CDR2 having the amino acid sequence of SEQ ID NO: 8 and a CDR3 having the amino acid sequence of SEQ ID NO: 9.
  • some embodiments relate to a library of synthetic polynucleotides encoding TCR alpha chains and TCR beta chains of a TCR capable of binding to a PRAME peptide having the sequence VLDGLDVLL (SEQ ID NO: 3), comprising
  • TCR alpha chain constant regions which are selected from the group of TCR alpha constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO: 1 ; wherein the amino acid at position 14 is selected from the group consisting of S, V, W, A, C, F, G, I, L, M and P; the amino acid at position 66 is selected from the group consisting of N, Q, S, T and Y; the amino acid at position 92 is selected from the group consisting of S, V, W, A C, F, G, I, L, M and P; the amino acid at position 93 is selected from the group consisting of S, V, W, A C, F, G, I, L, M and P; the amino acid at position 107 is selected from the group consisting of T, V, W, A, C, F, G, I, L, M and P; the amino acid at positionl 15 is selected from the group consisting of
  • amino acid at position 118 is selected from the group consisting of G,
  • TCR alpha chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 4, a CDR2 having the amino acid sequence of SEQ ID NO: 5 and a CDR3 having the amino acid sequence of SEQ ID NO: 6;
  • TCR beta chain constant regions which are selected from the group of TCR beta constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO: 2 wherein the amino acid at position 4 is selected from the group consisting of K, N; the amino acid at position 5 is selected from the group consisting of N, R,
  • amino acid at position 18 is selected from the group consisting of E, H, K, R and D; the amino acid at position 22 is selected from the group consisting of S, V,
  • amino acid at position 34 is selected from the group consisting of T, D,
  • amino acid at position 37 is selected from the group consisting of Y, F
  • amino acid at position 136 is selected from the group consisting of E, V
  • amino acid at position 157 is selected from the group consisting of T, V, W, A, C, F, G, I, L, M and P
  • amino acid at position 164 is selected from the group consisting of S,
  • the amino acid at position 177 is selected from the group consisting of S, F; the amino acid at position 178 is R or deleted; the amino acid at position 179 is G or deleted; b) TCR beta chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 7, a CDR2 having the amino acid sequence of SEQ ID NO: 8 and a CDR3 having the amino acid sequence of SEQ ID NO: 9.
  • the library comprises polynucleotides encoding a TCR alpha chain and a TCR beta chain, each polynucleotide comprising:
  • one or more internal ribosomal entry sites or self-cleaving peptides of the 2A family optionally one or more internal ribosomal entry sites or self-cleaving peptides of the 2A family.
  • the library comprises at least 1 x 10 5 , preferably 1 x 10 8 , more preferably 1 x 10 10 , even more preferably 1 x 10 11 , such as 2.25 x 10 13 unique molecules.
  • a library of vectors comprising the polynucleotide library as defined herein.
  • a library of cells comprising said library of vectors.
  • a library of cells expressing the polynucleotides as defined herein is encompassed.
  • a further aspect relates to a library of polypeptides encoded by the library of synthetic polynucleotides as defined herein.
  • Another aspect refers to the use of the library as described herein for identifying a TCR receptor with enhanced TCR alpha and TCR beta chain pairing.
  • a further aspect refers to a method for isolating a TCR with enhanced TCR alpha and beta chain pairing, comprising the steps:
  • TCR isolated from the TCR library as described herein is encompassed.
  • Another aspect refers to a library of TCR alpha chains and TCR beta chains, comprising
  • TCR alpha chains comprising: a) TCR alpha chain constant regions which are selected from the group of TCR alpha constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO 1 ; b) TCR alpha chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 4, a CDR2 having the amino acid sequence of SEQ ID NO: 5 and a CDR3 having the amino acid sequence of SEQ ID NO: 6;
  • TCR beta chains comprising a) TCR beta chain constant regions comprising constant regions which are selected from the group of TCR beta constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO: 15,
  • TCR beta chain constant regions comprising constant regions which are selected from the group of TCR beta constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO: 16; b) TCR beta chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 7, a CDR2 having the amino acid sequence of SEQ ID NO: 8 and a CDR3 having the amino acid sequence of SEQ ID NO: 9.
  • a further aspect refers to a kit comprising one or more of the libraries described herein.
  • Another aspect of the invention refers to nucleotide sequences of the synthetic polynucleotides defined herein in computer readable format. Accordingly, the invention also encompasses the amino acid sequences as defined herein in computer readable format.
  • the invention relates to a TCR capable of binding to a PRAME peptide having the sequence VLDGLDVLL (SEQ ID NO: 3), wherein the TCR comprises:
  • TCR alpha chain comprising
  • a variable TCR alpha region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 4, a CDR2 having the amino acid sequence of SEQ ID NO: 5 and a CDR3 having the amino acid sequence of SEQ ID NO: 6; and
  • variable TCR beta region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 7, a CDR2 having the amino acid sequence of SEQ ID NO: 8 and a CDR3 having the amino acid sequence of SEQ ID NO: 9; and - A constant TCR beta region comprising the sequence SEQ ID NO: 13.
  • Figure 1 A and 1 B show the amino acid sequence of the alpha chain constant region as defined in SEQ ID NO: 1 and the beta chain constant region of the TCR constant region as defined in SEQ: 16 enhancement library, respectively.
  • the introduced mutations are labelled from X01 -X08 in the alpha chain ( Figure 1A) and from X09-X14 in the beta chain ( Figure 1 B).
  • Donut charts show the distribution at which each amino acid appears in that position. Wild type version of amino acid sequence is highlighted in grey.
  • Figure 1 C visualizes the schematic map of library constructs.
  • Figure 2 shows a schematic overview of the screening procedure, which was used to identify a promising TCR clone derived from the library.
  • FIG. 3 Comparison of TCR expression on the surface of the promising Jurkat-ieGFP Biosensor library clone (8-9) and Jurkat-ieGFP Biosensor carrying PRAMEVLD-WT- TCR (WT).
  • Cells were stained with an antibody recognizing human monomorphic determinant of the a/
  • APC anti-panTCR-Allophycocyanin
  • APC anti-panTCR-Allophycocyanin
  • FIG. 6 TCR expression of reconstituted 8-9 TCR and WT-TCR on the surface of Jurkat-ieGFP Biosensor and CD8+ T cells from a healthy donor.
  • Cells were stained with anti-CD3-APC antibody, an antibody recognizing variable (31 chain of the TCR (anti-TCRBV9-PE), and live/dead marker 7-Amino-Actinomycin D (7AAD) and acquired at flow cytometer.
  • Graph presenting the level of TCR expression as a gMFI of TCRBV9-PE signal on BFP + cells is shown.
  • FIG. 7 Comparison of functional avidity between reconstituted 8-9 and WT-TCRs.
  • 8-9 TCR or WT-TCR-transduced Jurkat-ieGFP Biosensor cells were cocultured with T2 cells (targets) loaded with titrated concentrations of VLD peptide ranging from 1 O’ 10 to 10’ 5 M. Effector to target ratio was 2:1 (50000:25000 cells). After 20h of co-culture, cells were collected and stained with anti-HLA-A2-APC antibody to visualize target cells.
  • Percentage of eGFP positive cells and gMFI of eGFP signal on the HLA-A2 BFP + cells was measured with flow cytometry and plotted on the graph at different co-culture conditions.
  • B 8-9 TCR-, WT-TCR- or mock-transduced CD8 + T cells from a healthy donor were co-cultured with T2 cells loaded with titrated VLD peptide concentrations ranging from 10’ 10 to 10’ 5 M. After 24h, supernatants were collected and IFNy ELISA was performed. IFNy levels at different co-culture conditions are indicated on the graph.
  • FIG. 8 Testing TCR specificity of selected clones.
  • A-D Several clones (clone names given below x-axis) and WT were co-cultured with T2 cells loaded with either relevant VLDGLDVLL peptide (T2 + rel.), irrelevant peptide SLLQHLIGL (T2 + irrel.) or left alone (T cells only). After 24h of co-culture, cells were collected and percentage of eGFP positive cells and gMFI of eGFP signal on the transduced effector cells was measured with flow cytometry, gMFI of eGFP channel was plotted.
  • E-F Expression of precison paired TCRs in TCR-deficient Jurkat-76 CD+ ieGFP cells.
  • Transduced Jurkat-76 cells were analyzed for TCR expression by staining with anti TCR Vf3>1 (TRBV9) antibody [PE, clone BL37.2, Beckman Coulter] antibody and subsequent flow cytometric analysis.
  • TRBV9 TCR Vf3>1
  • PE clone BL37.2, Beckman Coulter
  • a first aspect of the invention relates to a library of synthetic polynucleotides encoding TCR alpha chains and TCR beta chains of a TCR capable of binding to a PRAME peptide having the sequence VLDGLDVLL (SEQ ID NO: 3), comprising
  • TCR alpha chain constant regions which are selected from the group of TCR alpha constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO 1
  • TCR alpha chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 4, a CDR2 having the amino acid sequence of SEQ ID NO: 5 and a CDR3 having the amino acid sequence of SEQ ID NO: 6;
  • TCR beta chain constant regions which are selected from the group of TCR beta constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO 2 i or TCR beta chain constant regions which are selected from the group of TCR beta constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO 15.
  • TCR beta chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 7, a CDR2 having the amino acid sequence of SEQ ID NO: 8 and a CDR3 having the amino acid sequence of SEQ ID NO: 9.
  • Another aspect refers to a library of TCR alpha chains and TCR beta chains, comprising
  • TCR alpha chains comprising: a) TCR alpha chain constant regions which are selected from the group of TCR alpha constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO 1 ; b) a TCR alpha chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 4, a CDR2 having the amino acid sequence of SEQ ID NO: 5 and a CDR3 having the amino acid sequence of SEQ ID NO: 6;
  • TCR beta chains comprising a) TCR beta chain constant regions comprising constant regions which are selected from the group of TCR beta constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO 15; or
  • TCR beta chain constant regions comprising constant regions which are selected from the group of TCR beta constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO 16.
  • TCR beta chain constant region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 7, a CDR2 having the amino acid sequence of SEQ ID NO: 8 and a CDR3 having the amino acid sequence of SEQ ID NO: 9.
  • SEQ ID NO: 1 defines TCR alpha chain constant regions which are set out in following amino acid sequence:
  • X at position 14 is selected from the group consisting of S, V, W, A, C, F, G, I, L, M and P;
  • X at position 66 is selected from the group consisting of N, Q, S, T and Y;
  • X at position 92 is selected from the group consisting of S, V, W, A C, F, G, I, L, M and P;
  • X at position 93 is selected from the group consisting of S, V, W, A C, F, G, I, L, M and P;
  • X at position 107 is selected from the group consisting of T, V, W, A, C, F, G, I, L, M and P;
  • X at positionl 15 is selected from the group consisting of S, V, W, A, C, F, G, I, L, M and P;
  • X at position 118 is selected from the group consisting of G, I, L, M, P, V, W, A, C and F; and
  • X at position 119 is selected from the group consisting of F, G, I, L, M, P, V, W, A and C;
  • X at position 14 corresponds to X01
  • X at position 66 corresponds to X02
  • X at position 92 corresponds to X03
  • X at position 93 corresponds to X04
  • X at position 107 corresponds to X05
  • X at position 115 corresponds to X06
  • X at position 118 corresponds to X07
  • X at position 119 corresponds to position X08 in Figure 1A.
  • SEQ ID NO: 2 defines TCR beta chain constant regions (including both Cbetal and Cbeta2 versions) which are set out in following amino acid sequence:
  • X at position 4 is selected from the group consisting of K, N;
  • X at position 5 is selected from the group consisting of N, R, D, E, H and K;
  • X at position 18 is selected from the group consisting of E, H, K, R and D;
  • X at position 22 is selected from the group consisting of S, V, W, A, C, F, G, I, L, M and P;
  • X at position 34 is selected from the group consisting of T, D, E, H, K, N and R;
  • X at position 37 is selected from the group consisting of Y, F;
  • X at position 136 is selected from the group consisting of E, V;
  • X at position 157 is selected from the group consisting of T, V, W, A, C, F, G, I, L, M and P;
  • X at position 164 is selected from the group consisting of S, V, W, A, C, F, G, I, L, M and P;
  • X at position 177 is selected from the group consisting of S, F;
  • X at position 178 is R or deleted
  • X at position 179 is G or deleted.
  • X at position 5 corresponds to X09
  • X at position 18 corresponds to X10
  • X at position 22 corresponds to X11
  • X at position 34 corresponds to X12
  • X at position 157 corresponds to X13
  • X at position 164 corresponds to X14 in Figure 1 B.
  • the constant region of the TCR beta chain occurs naturally either in the Cbetal version or in the Cbeta2 version, which are typically equally distributed in a population of natural unstimulated T cells.
  • the TCR beta chain constant regions may be a Cbetal version as set out in SEQ ID NO: 15 or a Cbeta2 version as set out in SEQ ID NO: 16.
  • TCR beta chain constant regions comprising constant regions which are selected from the group of TCR beta constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO: 2. cover both Cbetal and Cbeta2 versions.
  • SEQ ID NO: 15 defines TCR beta chain constant regions (Cbetal ) which are set out in following amino acid sequence: EDLNXVFPPEVAVFEPSXAEIXHTQKATLVCLAXGFFPDHVELSWWVNG KEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQ VQ FYG LS E N D E WTQ D RAKP VTQ I VS AE AWG RAD C G FTS VS YQ Q G VLS A TILYEILLGKAXLYAVLVXALVLMAMVKRKDF wherein
  • X at position 5 is selected from the group consisting of N, R, D, E, H and K;
  • X at position 18 is selected from the group consisting of E, H, K, R and D;
  • X at position 22 is selected from the group consisting of S, V, W, A, C, F, G, I, L, M and P;
  • X at position 34 is selected from the group consisting of T, D, E, H, K, N and R;
  • X at position 157 is selected from the group consisting of T, V, W, A, C, F, G, I, L, M and P;
  • X at position 164 is selected from the group consisting of S, V, W, A, C, F, G, I, L, M and P;
  • SEQ ID NO: 15 X09 to X14 are the identical positions as set out in Figure 1 B.
  • X at position 5 corresponds to X09
  • X at position 18 corresponds to X10
  • X at position 22 corresponds to X1 1
  • X at position 34 corresponds to X12
  • X at position 157 corresponds to X13
  • X at position 164 corresponds to X14 in Figure 1 B.
  • amino acids at the specific variable positions identified by the invention can only be selected from the amino acids as defined herein.
  • amino acids at the variable position according to the invention only the indicated alternative amino acid sequences can be selected.
  • SEQ ID NO: 16 defines TCR beta chain constant regions (Cbeta2) which are set out in following amino acid sequence:
  • X at position 5 is selected from the group consisting of N, R, D, E, H and K
  • X at position 18 is selected from the group consisting of E, H, K, R and D
  • X at position 22 is selected from the group consisting of S, V, W, A, C, F, G, I, L, M and P;
  • X at position 34 is selected from the group consisting of T, D, E, H, K, N and R;
  • X at position 157 is selected from the group consisting of T, V, W, A, C, F, G, I, L, M and P;
  • X at position 164 is selected from the group consisting of S, V, W, A, C, F, G, I, L, M and P;
  • the TCR alpha chain constant regions are selected from the group of TCR alpha constant regions which are at least about 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 1 and the TCR beta chain constant regions are selected from the group of TCR beta constant regions which are at least about 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 2.
  • the polynucleotides encoding TCR alpha chain constant regions are selected from the group of TCR alpha constant regions which are at least about 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 1 .
  • the polynucleotides encoding TCR beta chain constant regions are selected from the group of TCR beta constant regions which are at least about 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 2.
  • the polynucleotides encoding TCR beta chain constant regions are selected from the group of TCR beta constant regions which are at least about 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 15.
  • the determination of percent identity between multiple sequences is preferably accomplished using the AlignX application of the Vector NTI AdvanceTM 10 program (Invitrogen Corporation, Carlsbad CA, USA). This program uses a modified Clustal W algorithm (Thompson et al., 1994. Nucl Acids Res. 22: pp. 4673-4680; Invitrogen Corporation; Vector NTI AdvanceTM 10 DNA and protein sequence analysis software. User’s Manual, 2004, pp.389-662). The determination of percent identity is performed with the standard parameters of the AlignX application.
  • the polynucleotides encoding TCR alpha chains comprising constant regions are selected from the group of TCR alpha constant regions which are at least about 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 1.
  • the polynucleotides encoding TCR beta chains comprising constant regions are selected from the group of TCR beta constant regions which are at least about 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 2.
  • the polynucleotides encoding TCR beta chains comprising constant regions are selected from the group of TCR beta constant regions which are at least about 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 15.
  • the invention also relates to a library of synthetic polynucleotides encoding TCR alpha chains and TCR beta chains of a TCR capable of binding to a PRAME peptide having the sequence VLDGLDVLL (SEQ ID NO: 3), comprising
  • TCR alpha chain constant regions which are selected from the group of TCR alpha constant regions comprising the amino acid sequence as set out in SEQ ID NO: 1 ;
  • TCR alpha chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 4, a CDR2 having the amino acid sequence of SEQ ID NO: 5 and a CDR3 having the amino acid sequence of SEQ ID NO: 6;
  • TCR beta chains comprising a) TCR beta chain constant regions which are selected from the group of TCR beta constant regions comprising the amino acid sequence as set out in SEQ ID NO 15; or
  • TCR beta chain constant regions which are selected from the group of TCR beta constant regions comprising the amino acid sequence as set out in SEQ ID NO 16; b) TCR beta chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 7, a CDR2 having the amino acid sequence of SEQ ID NO: 8 and a CDR3 having the amino acid sequence of SEQ ID NO: 9.
  • TCR alpha chains comprising: a) TCR alpha chain constant regions which are selected from the group of TCR alpha constant regions comprising the amino acid sequence as set out in SEQ ID NO 1 ; b) TCR alpha chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 4, a CDR2 having the amino acid sequence of SEQ ID NO: 5 and a CDR3 having the amino acid sequence of SEQ ID NO: 6;
  • TCR beta chains comprising a) TCR beta chain constant regions comprising constant regions which are selected from the group of TCR beta constant regions comprising the amino acid sequence as set out in SEQ ID NO: 15;
  • TCR beta chain constant regions comprising constant regions which are selected from the group of TCR beta constant regions comprising the amino acid sequence as set out in SEQ ID NO: 16; b) TCR beta chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 7, a CDR2 having the amino acid sequence of SEQ ID NO: 8 and a CDR3 having the amino acid sequence of SEQ ID NO: 9.
  • Nucleic acid generally means a polymer of DNA or RNA, which can be singlestranded or double-stranded, synthesized or obtained (e.g., isolated and/or purified) from natural sources, which can contain natural, non-natural or altered nucleotides, and which can contain a natural, non-natural or altered internucleotide linkage, such as a phosphoroam idate linkage or a phosphorothioate linkage, instead of the phosphodiester found between the nucleotides of an unmodified oligonucleotide.
  • the nucleic acids described herein are recombinant.
  • the term "recombinant” refers to (i) molecules that are constructed outside living cells by joining natural or synthetic nucleic acid segments to nucleic acid molecules that can replicate in a living cell, or (ii) molecules that result from the replication of those described in (i) above.
  • the replication can be in vitro replication or in vivo replication.
  • the nucleic acids can be constructed based on chemical synthesis and/or enzymatic ligation reactions using procedures known in the art or commercially available (e.g. from GeneArt, Thermo Fisher and similar companies).
  • nucleic acid can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed upon hybridization (e.g., phosphorothioate derivatives and acridine substituted nucleotides).
  • the nucleic acid can comprise any nucleotide sequence which encodes any of the recombinant TCRs, polypeptides, or proteins, or functional portions or functional variants thereof.
  • the selection marker may be any useful selection marker, such as antibiotic resistance, fluourescent marker, binding epitope.
  • the selection marker may be thus selected from, but not limited to, CD20 or Her2/neu markers, or other conventional tags such as a myc-tag, FLAG-tag, T7-tag, HA (hemagglutinin)-tag, His-tag, S-tag, GST-tag, myc, T7, GST, or fluorescent marker, such as GFP, BFP, mTagBFP.
  • a TCR is composed of two different and separate protein chains, namely the TCR alpha (a) and the TCR beta (P) chain.
  • the TCR a chain comprises variable region (encoded by the variable (V), joining (J) genomic segments) and constant region (encoded by the constant genomic segment).
  • the TCR p chain comprises the variable region (encoded by the variable (V), diversity (D), joining (J) genomic segments) and constant region (encoded by the constant (C) genomic segment).
  • the rearranged V(D)J regions of both the TCR a and the TCR p chain contain hypervariable regions (CDR, complementarity determining regions), among which the CDR3 region determines the specific epitope recognition.
  • CDR hypervariable regions
  • the library contains TCR alpha chains, which contain only variations in their constant region within one library.
  • the remaining part, i.e. the variable region of the TCR is identical within one library.
  • the library contains TCR beta chains, which contain only variations in their constant region within one library.
  • the remaining part, i.e. the variable region of the TCR is identical within one library.
  • the library comprises polynucleotides encoding a TCR alpha chain and a TCR beta chain, each polynucleotide comprising:
  • one or more ribosomal entry sites or self-cleaving peptides of the 2A family are optionally selected from the group consisting of the 2A family.
  • the polynucleotide may contain one or more internal ribosomal entry sites (IRES) sequence or self-cleaving peptides of the 2A family, comprising the 2A peptide sequence derived from a porcine tsechovirus (P2A), derived from other species like Thosea asigna virus 2A peptide (T2A), derived from foot and mouth disease virus 2A peptide (F2A) (as described in Szymczak et al.: Development of 2A peptide-based strategies in the design of multicistronic vectors) and E2A, resulting in the expression a single messenger RNA (mRNA) molecule under the control of the viral promoter within the transduced cell.
  • IRS internal ribosomal entry sites
  • library refers to a collection of distinct molecules comprising typically more than 10 3 , more than 10 4 , more than 10 5 , more than 10 6 , more than 10 7 , more than 10 8 , more than 10 9 or even more than 10” members.
  • a library in the context of the present invention is a mixture of heterogeneous polypeptides or nucleic acids.
  • the library is composed of members, each of which has a single polypeptide or nucleic acid sequence. Sequence differences between library members are responsible for the diversity present in the library.
  • the library may take the form of a simple mixture of polypeptides or nucleic acids, or may be in the form of cells containing the library of nucleic acids. Preferably, a cell contains only one or a limited number of library members.
  • the nucleic acids are incorporated into expression vectors, in order to allow expression of the polypeptides encoded by the nucleic acids.
  • the library comprises at least 1 x 10 4 , at least 1 x 10 5 , at least 1 x 10 6 , at least 1 x 10 7 , at least 1 x 10 8 , at least 1 x 10 9 , preferably, 1 x 10 10 , more preferably 2.1 x 10 11 , such as 2.25 x 10 13 unique molecules.
  • the library has 1 x 10 6 to 1 x 10 15 , more preferably 1x 1O 10 to 1x10 14 unique molecules.
  • Comprising a number of unique molecules means that each of these molecules of this number differs to each of the other molecules of this number.
  • “unique molecules” means that these molecules exist only once in the library. It should be understood that there is likely to be more than one copy of many unique molecules in a particular physical realization.
  • a TCR alpha chain constant region may comprise an amino acid sequence which is at least about 80% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 12, 17, 19, 21 , 23, 25,
  • a TCR beta chain constant region may comprise an amino acid sequence which is at least about 80% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 13, 18, 20, 22, 24, 26,
  • the TCR alpha chain constant regions and the TCR beta chain constant region are selected from the following: a) TCR alpha chain constant region comprising an amino acid sequence which is at least about 80% identical to the amino acid sequence as set out in SEQ ID NO: 12 wherein the amino acids at position 14, 66, 92, 93, 107, 115, 118 and 119 are not changed and a TCR beta chain constant region comprising an amino acid sequence which is at least about 80% identical to the amino acid sequence as set out in SEQ ID NO: 13, wherein the amino acids at position 5, 18, 22, 34, 157 and 164 are not changed; b) TCR alpha chain constant region comprising an amino acid sequence which is at least about 80% identical to the amino acid sequence as set out in SEQ ID NO: 17 wherein the amino acids at position 14, 66, 92, 93, 107, 115, 118 and 119 are not changed and a TCR beta chain constant region comprising an amino acid sequence which is at least about 80% identical to the amino acid sequence as set out in S
  • the TCR alpha chain constant regions and the TCR beta chain constant region are selected from the following: a) TCR alpha chain constant region comprising the amino acid sequence as set out in SEQ ID NO: 12 and a TCR beta chain constant region comprising the amino acid sequence as set out in SEQ ID NO: 13; b) TCR alpha chain constant region comprising the amino acid sequence as set out in SEQ ID NO: 17 and a TCR beta chain constant region comprising the amino acid sequence as set out in SEQ ID NO: 18; c) TCR alpha chain constant region comprising the amino acid sequence as set out in SEQ ID NO: 19 and a TCR beta chain constant region comprising the amino acid sequence as set out in SEQ ID NO: 20; d) TCR alpha chain constant region comprising the amino acid sequence as set out in SEQ ID NO: 21 and a TCR beta chain constant region comprising the amino acid sequence as set out in SEQ ID NO: 22; e) TCR alpha chain constant region comprising the amino acid sequence as set out in SEQ ID NO
  • a “vector” is any molecule or composition that has the ability to carry a nucleic acid sequence into a suitable host cell where synthesis of the encoded polypeptide can take place.
  • a vector is a nucleic acid that has been engineered, using recombinant DNA techniques that are known in the art, to incorporate a desired nucleic acid sequence (e.g. a nucleic acid of the invention).
  • the vector may comprise DNA or RNA and/or comprise liposomes.
  • the vector may be a plasmid, shuttle vector, phagemide, cosmid, expression vector, retroviral vector, lentiviral vector, adenoviral vector or particle.
  • a vector may include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication.
  • a vector may also include one or more selectable marker genes and other genetic elements known to those of ordinary skill in the art.
  • a vector preferably is an expression vector that includes a nucleic acid according to the present invention operably linked to sequences allowing for the expression of said nucleic acid.
  • the vector is a retroviral particle.
  • a library of cells comprising said library of vectors.
  • a library of cells expressing the polynucleotides as defined herein is encompassed.
  • the above described vector comprising a nucleic acid sequence coding for the above described TCR may be introduced or the nucleic acid may be introduced by other means, e.g. In vitro transcribed RNA (ivtRNA) coding for said TCR may be introduced.
  • ivtRNA In vitro transcribed RNA
  • the cell may be a peripheral blood lymphocyte such as a T cell.
  • the method of cloning and exogenous expression of the TCR is for example described in Engels et al. (Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell, 23(4), 516-26. 2013).
  • the transduction of primary human T cells with a lentiviral vector is, for example, described in Cribbs “simplified production and concentration of lentiviral vectors to achieve high transduction in primary human T cells” BMC Biotechnol. 2013; 13: 98.
  • transduction refers to the process by which an exogenous nucleic acid sequence is introduced into a host cell, e.g. into a T cell. It is noted that introduction or transfer of nucleic acid sequences is not limited to the mentioned methods but can be achieved by any number of means including electroporation, microinjection, gene gun delivery, lipofection, superfection, infection by retroviruses or other suitable viruses for transduction or transfection.
  • the cell may be a T cell.
  • the T cell may express endogenous TCR chains.
  • the T cell may be a CD4+ or a CD8+ T cell.
  • the T cell is a CD8+ T cell.
  • the cell may be a Jurkat-ieGFP TCR A CD8+ cell.
  • a further aspect relates to a library of polypeptides encoded by the library of synthetic polynucleotides as defined herein. Another aspect refers to the use of the library as described herein for identifying a TCR receptor with enhanced TCR alpha and TCR beta chain pairing.
  • a further aspect refers to a method for isolating a TCR with enhanced TCR alpha and beta chain pairing, comprising the steps:
  • Wildtype with regard to “compared to wildtype” means in particular a TCR which is identical in the amino acid sequence to the TCR it is compared except that it contains in all positions X01 to X14 the wildtype amino acid.
  • the expression levels can be measured using flow cytometry as described herein.
  • the avidity may be measured e.g. by IFNy ELISA as described herein.
  • TCR isolated from the TCR library as described herein is encompassed.
  • the TCR isolated from the TCR library shows elevated expression levels of the heterologous TCR compared to wild type and/or elevated activation levels compared to wild type.
  • the invention relates to a TCR capable of binding to a PRAME peptide having the sequence VLDGLDVLL (SEQ ID NO: 3), wherein the TCR comprises: - A TCR alpha chain comprising a variable TCR alpha region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 4, a CDR2 having the amino acid sequence of SEQ ID NO: 5 and a CDR3 having the amino acid sequence of SEQ ID NO: 6; and
  • variable TCR beta chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 7, a CDR2 having the amino acid sequence of SEQ ID NO: 8 and a CDR3 having the amino acid sequence of SEQ ID NO: 9;
  • TCR beta region comprising the sequence SEQ ID NO: 13.
  • the TCR alpha chains comprise constant regions are selected from the group of TCR alpha constant regions which are at least about 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 1 and the TCR beta chains comprise constant regions are selected from the group of TCR beta constant regions which are at least about 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 2.
  • the TCRs according to the invention may show elevated expression levels of the heterologous TCR compared to wild type. Alternatively, or in addition, the TCRs according to the invention may show elevated activation levels compared to wild type. Preferably the TCRs according to the invention show elevated expression levels of the heterologous TCR compared to wild type and show elevated activation levels compared to wild type.
  • the amino acid in at least one of the variable positions, i.e. X01 to X14, is not the amino acid which occurs naturally in wild type. That means that preferably in at least two, more preferably at least three, even more preferably at least four, such as at least five, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11 , at least 12, at least 13, such as in all 14 positions of X01 to X14, the amino acid is not the amino acid which occurs naturally in wild type.
  • the term “not the amino acid which occurs naturally in wild type” means in the context of this application that it is substituted by an amino acid as defined for the variable positions X1 to X14, which is not the wild type amino acid for this position.
  • a further aspect refers to a kit comprising one or more of the libraries described herein.
  • Another aspect of the invention refers to nucleotide sequences of the synthetic polynucleotides defined herein in computer readable format. Accordingly, the invention also encompasses the amino acid sequences as defined herein in computer readable format.
  • Nucleic acid generally means a polymer of DNA or RNA, which can be singlestranded or double-stranded, which can contain natural, non-natural or altered nucleotides, and which can contain a natural, non-natural or altered internucleotide linkage, such as a phosphoroam idate linkage or a phosphorothioate linkage, instead of the phosphodiester found between the nucleotides of an unmodified oligonucleotide.
  • the nucleic acid may be made synthetically, e.g. using art-recognized nucleic acid chemistry or enzymatically using, e.g. a polymerase.
  • the nucleic acids described herein are recombinant.
  • the term “recombinant” refers to (i) molecules that are constructed outside living cells by joining natural or synthetic nucleic acid segments to nucleic acid molecules that can replicate in a living cell, or (ii) molecules that result from the replication of those described in (i) above.
  • the replication can be in vitro replication or in vivo replication.
  • the nucleic acids can be constructed based on chemical synthesis and/or enzymatic ligation reactions using procedures known in the art or commercially available (e.g. from Genscript, Thermo Fisher and similar companies).
  • nucleic acid can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed upon hybridization (e.g., phosphorothioate derivatives and acridine substituted nucleotides).
  • the nucleic acid can comprise any nucleotide sequence which encodes any of the recombinant TCRs, polypeptides, or proteins, or functional portions or functional variants thereof.
  • the nucleic acid encoding the TOR may be modified. Useful modifications in the overall nucleic acid sequence may be codon optimization. Alterations may be made which lead to conservative substitutions within the expressed amino acid sequence. These variations can be made in complementarity determining and non-complementarity determining regions of the amino acid sequence of the TCR chain that do not affect function. Usually, additions and deletions should not be performed in the CDR3 region.
  • recombinant and “recombinant TCR” as used in the present application refers to TCRs that have been introduced by any of the genetic engineering techniques into the T cells.
  • the “recombinant TCR” also termed “exogenous TCR” may be engineered or may be a naturally occurring TCR which has a desired antigen specificity and which was isolated.
  • these recombinant TCRs which were not endogenous to the T cell population, i.e. were not naturally expressed in the T cell population, i.e. were not expressed in the T cell population before transfer of the recombinant TCR.
  • the amino acid sequence of the TCR is modified to comprise a detectable label, a therapeutic agent or pharmacokinetic modifying moiety.
  • Non-limiting examples for detectable labels are radiolabels, fluorescent labels, nucleic acid probes, enzymes and contrast reagents.
  • Therapeutic agents which may be associated with the TCRs include radioactive compounds, immune-modulators, enzymes or chemotherapeutic agents.
  • the therapeutic agents could be enclosed by a liposome linked to TCR so that the compound can be released slowly at the target site. This will avoid damage during the transport in the body and ensure that the therapeutic agent, e.g. toxin, has maximum effect after binding of the TCR to the relevant antigen presenting cells.
  • Other examples for therapeutic agents are: peptide cytotoxins, i.e.
  • cytotoxic agents i.e. compounds with the ability to kill mammalian cells having a molecular weight of less than 700 Daltons. Such compounds could contain toxic metals capable of having a cytotoxic effect.
  • these small molecule cytotoxic agents also include pro-drugs, i.e. compounds that decay or are converted under physiological conditions to release cytotoxic agents.
  • Such agents may for example include docetaxel, gemcitabine, cisplatin, maytansine derivatives, rachelmycin, calicheamicin, etoposide, ifosfamide, irinotecan, porfimer sodium photofrin II, temozolomide, topotecan, trimetrexate glucoronate, mitoxantrone, auristatin E, vincristine and doxorubicin; radionuclides, such as, iodine 131 , rhenium 186, indium 111 , yttrium 90. bismuth 210 and 213, actinium 225 and astatine 213.
  • immune-stimulators also known as immunostimulants, i.e. immune effector molecules which stimulate immune response.
  • immune-stimulators are cytokines such as IL-2 and IFN-y, antibodies or fragments thereof, including anti-T cell or NK cell determinant antibodies (e.g anti-CD3, anti-CD28 or anti-CD16); alternative protein scaffolds with antibody like binding characteristics; Superantigens, i.e.
  • T cell receptor molecules on human T lymphocytes are non-covalently associated with the CD3 (T3) molecular complex on the cell surface. Perturbation of this complex with anti-CD3 monoclonal antibodies induces T cell activation.
  • some embodiments refer to a TCR as described herein associated (usually by fusion to an N-or C-terminus of the alpha or beta chain) with an anti-CD3 antibody, or a functional fragment or variant of said anti-CD3 antibody.
  • Antibody fragments and variants/analogues which are suitable for use in the compositions and methods described herein include minibodies, Fab fragments, F(ab ⁇ '>)2fragments, dsFv and scFv fragments, NanobodiesTM (Ablynx (Belgium), molecules comprising synthetic single immunoglobulin variable heavy chain domain derived from a camelid (e.g.
  • Domain Antibodies comprising an affinity matured single immunoglobulin variable heavy chain domain or immunoglobulin variable light chain domain (Domantis (Belgium) or alternative protein scaffolds that exhibit antibody-like binding characteristics such as Affibodies (comprising engineered protein A scaffold Affibody (Sweden)) or Anticalins (comprising engineered anticalins Pieris (German)).
  • the therapeutic agent may preferably be selected from the group consisting of an immune effector molecule, a cytotoxic agent and a radionuclide.
  • the immune effector molecule is a cytokine.
  • the pharmacokinetic modifying moiety may be for example at least one polyethylene glycol repeating unit, at least one glycol group, at least one sialyl group or a combination thereof.
  • the association of at least one polyethylene glycol repeating unit, at least one glycol group, at least one sialyl group may be caused in a number of ways known to those skilled in the art.
  • the units are covalently linked to the TCR.
  • the TCRs according to the invention can be modified by one or several pharmacokinetic modifying moieties.
  • the soluble form of the TCR is modified by one or several pharmacokinetic modifying moieties.
  • the pharmacokinetic modifying moiety may achieve beneficial changes to the pharamacokinetic profile of the therapeutic, for example improved plasma half-life, reduced or enhanced immunogenicity, and improved solubility.
  • llse functional moieties and modifications include “suicide” or “safety switches” that can be used to shut off effector host cells carrying an inventive TCR in a patient’s body.
  • suicide or “safety switches” that can be used to shut off effector host cells carrying an inventive TCR in a patient’s body.
  • An example is the inducible Caspase 9 (iCasp9) “safety switch” described by Gargett and Brown Front Pharmacol. 2014; 5: 235.
  • effector host cells are modified by well-known methods to express a Caspase 9 domain whose dimerization depends on a small molecule dimerizer drug such as AP1903/CIP, and results in rapid induction of apoptosis in the modified effector cells.
  • the system is for instance described in EP2173869 (A2).
  • suicide e.g. Herpes Simplex Virus thymidine kinase (HSV-TK), expression of CD20 and subsequent depletion using anti-CD20 antibody or myc tags (Kieback et al, Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):623-8).
  • TCRs with an altered glycosylation pattern are also envisaged herein.
  • glycosylation patterns can depend on the amino acid sequence (e.g., the presence or absence of particular glycosylation amino acid residues, discussed below) and/or the host cell or organism in which the protein is produced.
  • Glycosylation of polypeptides is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue.
  • N- linked glycosylation sites to the binding molecule is conveniently accomplished by altering the amino acid sequence such that it contains one or more tri-peptide sequences selected from asparagine-X-serine and asparagine-X-threonine (where X is any amino acid except proline).
  • O-linked glycosylation sites may be introduced by the addition of or substitution by, one or more serine or threonine residues to the starting sequence.
  • glycosylation of TCRs is by chemical or enzymatic coupling of glycosides to the protein.
  • the sugar(s) may be attached to (a) arginine and histidine, (b) free carboxyl groups, (c) free sulfhydryl groups such as those of cysteine, (d) free hydroxyl groups such as those of serine, threonine, or hydroxyproline, (e) aromatic residues such as those of phenylalanine, tyrosine, or tryptophan, or (f) the amide group of glutamine.
  • deglycosylation i.e., removal of carbohydrate moieties present on the binding molecule
  • deglycosylation may be accomplished chemically, e.g. by exposing the TCRs to trifluoromethanesulfonic acid, or enzymatically by employing endo- and exo-glycosidases.
  • a drug such as a small molecule compound
  • Linkage can be achieved via covalent bonds, or non-covalent interactions such as through electrostatic forces.
  • Various linkers known in the art, can be employed in order to form the drug conjugates.
  • the TCR in particular a soluble form of the inventive TCR can additionally be modified to introduce additional domains which aid in identification, tracking, purification and/or isolation of the respective molecule (tags).
  • the TCR a chain or the TCR [3 chain may be modified to comprise an epitope tag.
  • Epitope tags are useful examples of tags that can be incorporated into the TCR of the invention.
  • Epitope tags are short stretches of amino acids that allow for binding of a specific antibody and therefore enable identification and tracking of the binding and movement of soluble TCRs or host cells within the patient’s body or cultivated (host) cells. Detection of the epitope tag, and hence, the tagged TCR, can be achieved using a number of different techniques.
  • Tags can further be employed for stimulation and expansion of host cells carrying an inventive TCR by cultivating the cells in the presence of binding molecules (antibodies) specific for said tag.
  • the TCR can be modified in some instances with various mutations that modify the affinity and the off-rate of the TCR with the target antigen.
  • the mutations may increase the affinity and/or reduce the off-rate.
  • the TCR may be mutated in at least one CDR and the variable domain framework region thereof.
  • the CDR regions of the TCR are not modified or in vitro affinity maturated such as for the TCR receptors in the examples. This means that the CDR regions have naturally occurring sequences. This can be advantageous, since in vitro affinity maturation may lead to immunogenicity to the TCR molecule. This may lead to the production of anti-drug antibodies decreasing or inactivating the therapeutic effect and the treatment and /or induce adverse effects.
  • the mutation may be one or more substitution(s), deletion(s) or insertions(s). These mutations may be introduced by any suitable method known in the art, such as polymerase chain reaction, restriction enzyme-based cloning, ligation independent cloning procedures, which are described for Example in Sambrook, Molecular Cloning - 4 th Edition (2012) Cold Spring Harbor Laboratory Press.
  • compositions comprising the TCR as described herein, the nucleic acid encoding the TCR, the vector comprising said nucleic acid and/or the cell comprising said TCR.
  • active components of the present invention are preferably used in such a pharmaceutical composition, in doses mixed with an acceptable carrier or carrier material, that the disease can be treated or at least alleviated.
  • Such a composition can (in addition to the active component and the carrier) include filling material, salts, buffer, stabilizers, solubilizers and other materials, which are known state of the art.
  • pharmaceutically acceptable defines a non-toxic material, which does not interfere with effectiveness of the biological activity of the active component.
  • the choice of the carrier is dependent on the application.
  • the pharmaceutical composition may contain additional components which enhance the activity of the active component or which supplement the treatment. Such additional components and/or factors can be part of the pharmaceutical composition to achieve synergistic effects or to minimize adverse or unwanted effects.
  • An appropriate application is a parenteral application, for example intramuscular, subcutaneous, intramedular injections as well as intrathecal, direct intraventricular, intravenous, intranodal, intraperitoneal or intratumoral injections.
  • the intravenous injection is the preferred treatment of a patient.
  • the pharmaceutical composition is an infusion or an injection.
  • An injectable composition is a pharmaceutically acceptable fluid composition comprising at least one active ingredient, e.g. an expanded T cell population (for example autologous or allogenic to the patient to be treated) expressing a TCR.
  • the active ingredient is usually dissolved or suspended in a physiologically acceptable carrier, and the composition can additionally comprise minor amounts of one or more non-toxic auxiliary substances, such as emulsifying agents, preservatives, and pH buffering agents and the like.
  • Such injectable compositions that are useful for use with the fusion proteins of this disclosure are conventional; appropriate formulations are well known to those of ordinary skill in the art.
  • the pharmaceutical composition comprises at least one pharmaceutically acceptable carrier.
  • another aspect of the invention refers to the TCR as described herein, the polypeptide comprising a functional portion of said TCR, the multivalent TCR complex according as described herein, the nucleic acid encoding said TCR, the vector comprising said nucleic acid, the cell comprising said TCR, or the antibody specifically binding to a portion of the TCR as described herein for use as a medicament.
  • Some embodiments refer to the TCR as described herein, the polypeptide comprising a functional portion of said TCR, the multivalent TCR complex according as described herein, the nucleic acid encoding said TCR, the vector comprising said nucleic acid, the cell comprising said TCR for use in the treatment of cancer.
  • the cancer is a hematological cancer or a solid tumor.
  • Hematological cancers also called blood cancers which do not form solid tumors and therefore are dispersed in the body.
  • hematological cancers are leukemia, lymphoma or multiple myeloma.
  • sarcomas There are two major types of solid tumors, sarcomas and carcinomas.
  • Sarcomas are for example tumors of the blood vessel, bone, fat tissue, ligament, lymph vessel, muscle or tendon.
  • the cancer is selected from the group consisting of prostate cancer, uterine cancer, thyroid cancer, testicular cancer, renal cancer, pancreatic cancer, ovarian cancer, esophageal cancer, non-small-cell lung cancer, lung adenocarcinoma, squamous cell carcinoma, non-Hodgkin’s lymphoma, multiple myeloma, melanoma, hepatocellular carcinoma, head and neck cancer, gastric cancer, endometrial cancer, cervical cancer, colorectal cancer, stomach adenocarcinoma, cholangiocarcinoma, breast cancer, bladder cancer, myeloid leukemia and acute lymphoblastic leukemia, carcinoma, acute myeloid leukemia, myelodysplastic syndromes and multiple myeloma, sarcoma or osteosarcoma.
  • the cancer is a hematological cancer.
  • the hematological cancer may be acute myeloid leukemia, myelodysplastic syndromes and multiple myeloma.
  • pharmaceutical compositions and kits containing one or more of (i) an isolated TCR as described herein; (ii) viral particles comprising a nucleic acid encoding a recombinant TCR; (iii) immune cells, such as T cells or NK cells, modified to express a recombinant TCR as described herein; (iv) nucleic acids encoding a recombinant TCR as described herein.
  • compositions comprising lentiviral vector particles comprising a nucleotide sequence encoding a recombinant TCR described herein (or T cells that have been modified using the vector particles described herein to express a recombinant TCR). Such compositions can be administered to subjects in the methods of the present disclosure as described further herein.
  • compositions comprising the modified T cells as described herein can be utilized in methods and compositions for adoptive immunotherapy in accordance with known techniques, or variations thereof that will be apparent to those skilled in the art based on the instant disclosure.
  • the cells are formulated by first harvesting them from their culture medium, and then washing and concentrating the cells in a medium and container system suitable for administration (a "pharmaceutically acceptable" carrier) in a treatment-effective amount.
  • a medium and container system suitable for administration a "pharmaceutically acceptable” carrier
  • Suitable infusion medium can be any isotonic medium formulation, typically normal saline, Normosol R (Abbott) or Plasma-Lyte A (Baxter), but also 5% dextrose in water or Ringer's lactate can be utilized.
  • the infusion medium can be supplemented with human serum albumin.
  • the number of cells for an effective treatment in the composition is typically greater than 10 cells, and up to 10 6 , up to and including 10 8 or 10 9 cells and can be more than 10 1 ° cells.
  • the number of cells will depend upon the ultimate use for which the composition is intended as will the type of cells included therein.
  • the cells are generally in a volume of a liter or less, can be 500 ml or less, even 250 ml or 100 ml or less.
  • the density of the desired cells is typically greater than 10 6 cells/ml and generally is greater than 10 7 cells/ml, generally 10 8 cells/ml or greater.
  • compositions provided herein can be in various forms, e.g., in solid, liquid, powder, aqueous, or lyophilized form.
  • suitable pharmaceutical carriers are known in the art.
  • Such carriers and/or additives can be formulated by conventional methods and can be administered to the subject at a suitable dose.
  • Stabilizing agents such as lipids, nuclease inhibitors, polymers, and chelating agents can preserve the compositions from degradation within the body.
  • a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent may be included.
  • kits can optionally include one or more components such as instructions for use, devices, and additional reagents, and components, such as tubes, containers and syringes for practice of the methods.
  • Exemplary kits can include the nucleic acids encoding the recombinant TCRs, the recombinant TCR polypeptides, or viruses provided herein, and can optionally include instructions for use, a device for detecting a virus in a subject, a device for administering the compositions to a subject, and a device for administering the compositions to a subject.
  • Kits comprising polynucleotides encoding a gene of interest (e.g., a recombinant TCR) are also contemplated herein.
  • Kits comprising a viral vector encoding a sequence of interest (e.g., a recombinant TCR) and optionally, a polynucleotide sequence encoding an immune checkpoint inhibitor are also contemplated herein.
  • Kits contemplated herein also include kits for carrying out the methods for detecting the presence of polynucleotides encoding any one or more of the TCRs disclosed herein.
  • diagnostic kits may include sets of appropriate amplification and detection primers and other associated reagents for performing deep sequencing to detect the polynucleotides encoding TCRs disclosed herein.
  • the kits herein may comprise reagents for detecting the TCRs disclosed herein, such as antibodies or other binding molecules. Diagnostic kits may also contain instructions for determining the presence of the polynucleotides encoding the TCRs disclosed herein or for determining the presence of the TCRs disclosed herein.
  • a kit may also contain instructions.
  • Kits provided herein also can include a device for administering a composition described herein to a subject. Any of a variety of devices known in the art for administering medications or vaccines can be included in the kits provided herein. Exemplary devices include, but are not limited to, a hypodermic needle, an intravenous needle, a catheter, a needle-less injection device, an inhaler, and a liquid dispenser, such as an eyedropper.
  • the device for administering a virus of the kit will be compatible with the virus of the kit; for example, a needle-less injection device such as a high pressure injection device can be included in kits with viruses not damaged by high pressure injection, but is typically not included in kits with viruses damaged by high pressure injection.
  • a needle-less injection device such as a high pressure injection device can be included in kits with viruses not damaged by high pressure injection, but is typically not included in kits with viruses damaged by high pressure injection.
  • Kits provided herein also can include a device for administering a compound, such as a T cell activator or stimulator, or a TLR agonist, such as a TLR4 agonist to a subject.
  • a device for administering a compound such as a T cell activator or stimulator, or a TLR agonist, such as a TLR4 agonist to a subject.
  • a compound such as a T cell activator or stimulator
  • a TLR agonist such as a TLR4 agonist
  • kits provided herein can be included in the kits provided herein.
  • Exemplary devices include a hypodermic needle, an intravenous needle, a catheter, a needle-less injection, but are not limited to, a hypodermic needle, an intravenous needle, a catheter, a needle-less injection device, an inhaler, and a liquid dispenser such as an eyedropper.
  • the device for administering the compound of the kit will be compatible with the desired method of administration of the compound.
  • TCR-C-enhancement library is a DNA library carrying 10 11 TCR a and [3 constant region variants of the PRAMEVLD-TCR and was generated using TRIM technology.
  • TCR constant regions contain six mutation sites in the TCR C-
  • Amino acid substitutions were chosen based on a broad literature evaluation for residues that are important for: improving TCR signal transduction through better TCR interaction with CD3 subunits; post-translational modifications that might be detrimental for TCR avidity (e.g N-linked glycosylated positions); binding to lipid rafts resulting in better clustering [Cohen et.al. , Cancer Res. 2007; Kuball et.
  • the sequences coding for alpha and beta chains of PRAMEVLD-TCR are separated with a linker and P2A sequence coding for self-cleaving peptide ( Figure 1C).
  • Library contains also a mTag BFP sequence preceded with a linker and P2A sequence.
  • the library was cloned into a retroviral vector that allows transduction of the library into recipient T cells with the aim of finding optimal TCR mutation combinations for increased functional avidity.
  • Retroviral supernatants of the library as well as PRAMEVLD-WT-TCR construct which differed from library PRAMEVLD-TCR amino acid sequence only in regard to the mutation sites in the constant a and [3 chains ( Figure 1 A and B), were produced in HEK293FT cells.
  • Viral supernatants were titrated and diluted to achieve multiplicity of infection (MOI) equal or lower than 1 , thus maximizing the number of cells with a single integration of a viral particle.
  • MOI multiplicity of infection
  • a TCR signal reporter system which allows high-throughput flow cytometry-based screening for exogenously introduced and activated TCRs, was generated.
  • VLD VLDGLDVLL
  • CD3 can be only detected on the cell surface if it is associated with an alpha and beta TCR heterodimer, thus cells without a paired alpha beta TCR will be CD3 negative and the amount of CD3 will be directly related to the amount of the alpha-beta paired chains of the TCR. Therefore, CD3 can be used as selection marker. Based on CD3 positivity, Jurkat-ieGFP Biosensor cells successfully expressing TCR were selected. Additionally, through gating on cells with high expression of eGFP, only cells transduced with highly functional TCRs were isolated. Single cell clones were expanded to the numbers allowing further testing for reactivity to T2 cells loaded with 10’ 5 M concentration of VLD peptide or tumor cell lines with differential expression of PRAME antigen.
  • PRAMEvLD-WT-TCR-Jurkat-ieGFP Biosensors were used as a control throughout the whole screening process. Based on the superior functionality compared to the WT-TCR, one promising clone caring TCRs from the library was selected.
  • T2 cells expressing the HLA of interest were loaded with 10’ 5 M concentration of relevant (VLD) or control SLLQHLIGL (SLL; SEQ ID NO: 14) peptide and co-cultured with the library clone 8-9 or the WT cells.
  • VLD relevant
  • SLL SLLQHLIGL
  • eGFP signal induced upon TCR activation was measured with flow cytometry. The specific activation could only be seen when the library clone or WT were co-cultured with T2 cells loaded with relevant peptide, thereby confirming the peptide specificity of the selected clone.
  • the library clone showed increased expression of inducible eGFP levels in comparison to WT measured by flow cytometry.
  • the selected library clone was shown to carry highly functional TCRs, which are able to recognize naturally processed and presented peptide more efficiently than WT. Reconstitution of 8-9 clone derived TCR and validation
  • TCR sequence derived from clone 8-9 (called 8-9 TCR) and WT-TCR sequence, which differed from 8-9 TCR nucleotide sequence only in regard to the mutation sites in the constant a and [3 chains introduced through the library, were reconstituted in Jurkat-ieGFP Biosensor cells or in CD8+ T cells derived from three healthy donors. Reconstitution was performed with retroviral transduction at high MOI. With comparable expression of BFP (transduction efficiency marker), TCR expression levels were highly increased in 8-9 TCR transduced Jurkat-ieGFP Biosensor cells or CD8+ T cells from all three healthy donors compared to the same cell types transduced with WT-TCR (Figure 6).
  • 8-9 TCR TCR sequence derived from clone 8-9
  • WT-TCR sequence which differed from 8-9 TCR nucleotide sequence only in regard to the mutation sites in the constant a and [3 chains introduced through the library
  • TCR 8-9 compared to the WT-TCR is higher in both, Jurkat-ieGFP cells and CD8+ T cells (Figure 6).
  • the difference between WT-TCR transduced and 8- 9-TCR transduced CD8+ T cells from healthy donors is significantly smaller compared with the difference of WT-TCR transduced and 8-9-TCR transduced ieGFP Jurkat cells.
  • the reactivity of the 8-9 TCR transduced CD8+ T cells is markedly higher than that of the WT-TCR transduced T cells, comparable to the results seen in ieGFP-Jurkat cells (Figure 7). This supports that the TCRs described herein identified by the method of the invention not only show an increased surface expression but also a reduced mispairing with the endogenous TCR chains compared to WT-TCR.
  • TCR or WT-TCR-transduced Jurkat-ieGFP Biosensor cells were co-cultured with T2 cells loaded with titrated concentrations of VLD peptide ranging from 1 O’ 10 to 10’ 5 M. After 20h of co-culture, percentage of eGFP positive cells as well as geometric mean fluorescence intensity of eGFP signal on the BFP positive cells (transduced cells) was assessed with flow cytometry. In both read-outs 8-9 TCR-transduced cells showed higher signals when compared to the WT-TCR-transduced cells ( Figure 7A).
  • Transduced Jurkat-76 cells were analyzed for TOR expression by staining with anti TCR Vf3>1 (TRBV9) antibody [PE, clone BL37.2, Beckman Coulter] antibody and subsequent flow cytometric analysis.
  • TRBV9 antibody anti TCR Vf3>1
  • ppTCR clones showed equal or higher expression of the TCR on the cell surface of Jurkat 76 -/- cells compared to wildtype TCR transduce Jurkat 76 -/- cells (Fig. 8E-F).
  • the application further comprises the following items:
  • Item 1 A library of synthetic polynucleotides encoding TCR alpha chains and TCR beta chains of a TCR capable of binding to a PRAME peptide having the sequence VLDGLDVLL (SEQ ID NO: 3), comprising
  • TCR alpha chain constant regions which are selected from the group of TCR alpha constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO: 1 ;
  • TCR alpha chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 4, a CDR2 having the amino acid sequence of SEQ ID NO: 5 and a CDR3 having the amino acid sequence of SEQ ID NO: 6;
  • TCR beta chains comprising a) - TCR beta chain constant regions which are selected from the group of TCR beta constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO: 15; or
  • TCR beta chain constant regions which are selected from the group of TCR beta constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO: 16; b) TCR beta chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 7, a CDR2 having the amino acid sequence of SEQ ID NO: 8 and a CDR3 having the amino acid sequence of SEQ ID NO: 9.
  • Item 2 A library of synthetic polynucleotides encoding TCR alpha chains and TCR beta chains of a TCR capable of binding to a PRAME peptide having the sequence VLDGLDVLL (SEQ ID NO: 3), comprising
  • TCR alpha chain constant regions which are selected from the group of TCR alpha constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO: 1 : wherein the amino acid at position 14 is selected from the group consisting of S, V, W, A, C, F, G, I, L, M and P; the amino acid at position 66 is selected from the group consisting of N, Q, S, T and Y; the amino acid at position 92 is selected from the group consisting of S, V, W, A C, F, G, I, L, M and P; the amino acid at position 93 is selected from the group consisting of S, V, W, A C, F, G, I, L, M and P; the amino acid at position 107 is selected from the group consisting of T, V, W, A, C, F, G, I, L, M and P; the amino acid at positionl 15 is selected from the group consisting of
  • TCR beta chain constant regions which are selected from the group of TCR beta constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO: 15 wherein the amino acid at position 5 is selected from the group consisting of N, R,
  • amino acid at position 18 is selected from the group consisting of E, H, K, R and D
  • amino acid at position 22 is selected from the group consisting of S, V, W, A, C, F, G, I, L, M and P
  • amino acid at position 34 is selected from the group consisting of T, D,
  • amino acid at position 157 is selected from the group consisting of T,
  • TCR beta chain constant regions which are selected from the group of TCR beta constant regions which are at least about 80% identical to the amino acid sequence in SEQ ID NO: 16; wherein the amino acid at position 5 is selected from the group consisting of N, R, D, E, H and K; the amino acid at position 18 is selected from the group consisting of E, H, K, R and D; the amino acid at position 22 is selected from the group consisting of S, V, W, A, C, F, G, I, L, M and P; the amino acid at position 34 is selected from the group consisting of T, D, E, H, K, N and R; the amino acid at position 157 is selected from the group consisting of T,
  • Item 3 Library of synthetic polynucleotides according to item 1 or 2, wherein the TCR specifically recognizes the amino acid sequence of SEQ ID NO: 3, which is presented by a molecule encoded by an HLA-A*02 gene.
  • Item 4 Library of synthetic polynucleotides according to items 1 to 3, wherein the library comprises polynucleotides encoding a TCR alpha chain and a TCR beta chain, each polynucleotide comprising:
  • one or more ribosomal entry site or self-cleaving peptides of the 2A family optionally one or more ribosomal entry site or self-cleaving peptides of the 2A family.
  • Item 5 Library of synthetic polynucleotides according to any one of items 1 to 4, wherein the library comprises at least 1 x 10 5 , preferably, 1 x 10 10 , more preferably 2.1 x 10 11 , such as 2.25 x 10 13 unique molecules.
  • Item 6 A library of vectors comprising the polynucleotide library according to any one of items 1 to 5.
  • Item 7 The library of vectors according to item 6, wherein the vectors are retroviral vectors.
  • Item 8 A library of cells, comprising the library of vectors according to item 7.
  • Item 9 A library of cells expressing the polynucleotides defined in items 1 to 4.
  • Item 10 A library of polypeptides encoded by the library of synthetic polynucleotides according to items 1 to 5.
  • Item 11 Use of the library of items 1 to 10 for identifying a TCR receptor with enhanced TCR alpha and TRC beta chain pairing.
  • Item 12 A method for isolating a library derived TCR with enhanced TCR alpha and beta chain pairing, comprising the steps:
  • Item 13 A TCR isolated from the TCR library as described in item 11 .
  • Item 14 A library of TCR alpha chains and TCR beta chains, comprising
  • - TCR alpha chains comprising: a) TCR alpha chain constant regions which are selected from the group of TCR alpha constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO 1 ; b) TCR alpha chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 4, a CDR2 having the amino acid sequence of SEQ ID NO: 5 and a CDR3 having the amino acid sequence of SEQ ID NO: 6; - TCR beta chains comprising a) TCR beta chain constant regions comprising constant regions which are selected from the group of TCR beta constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO 15; or
  • TCR beta chain constant regions which are selected from the group of TCR beta constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO 16; b) TCR beta chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 7, a CDR2 having the amino acid sequence of SEQ ID NO: 8 and a CDR3 having the amino acid sequence of SEQ ID NO: 9.
  • Item 15 A library of TCR alpha chains and TCR beta chains, comprising
  • TCR alpha chains comprising: a) TCR alpha chain constant regions which are selected from the group of TCR alpha constant regions which are at least about 80% identical to the amino acid sequence as set out in SEQ ID NO 1 wherein
  • X at position 14 is selected from the group consisting of S, V, W, A, C, F, G, I, L, M and P;
  • X at position 66 is selected from the group consisting of N, Q, S, T and Y;
  • X at position 92 is selected from the group consisting of S, V, W, A C, F, G, I, L, M and P;
  • X at position 93 is selected from the group consisting of S, V, W, A C, F, G, I, L, M and P;
  • X at position 107 is selected from the group consisting of T, V, W, A, C, F, G, I, L, M and P;
  • X at positionl 15 is selected from the group consisting of S, V, W, A, C, F, G, I, L, M and P;
  • X at position 118 is selected from the group consisting of G, I, L, M, P, V, W, A, C and F; and X at position 119 is selected from the group consisting of F, G, I, L, M, P, V, W, A and C; b) TOR alpha chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 4, a CDR2 having the amino acid sequence of SEQ ID NO: 5 and a CDR3 having the amino acid sequence of SEQ ID NO: 6;
  • TCR beta chain constant regions comprising constant regions which are selected from the group of TCR beta constant regions which are at least about 80% identical to the amino acid sequence as set in SEQ ID NO: 2, wherein the amino acid at position 4 is selected from the group consisting of K, N; the amino acid at position 5 is selected from the group consisting of N, R, D, E, H and K; the amino acid at position 18 is selected from the group consisting of E, H, K, R and D; the amino acid at position 22 is selected from the group consisting of
  • amino acid at position 34 is selected from the group consisting of
  • the amino acid at position 37 is selected from the group consisting of Y, F; the amino acid at position 136 is selected from the group consisting of E, V; the amino acid at position 157 is selected from the group consisting of T, V, W, A, C, F, G, I, L, M and P; and the amino acid at position 164 is selected from the group consisting of S, V, W, A, C, F, G, I, L, M and P; the amino acid at position 177 is selected from the group consisting of S, F; the amino acid at position 178 is R or deleted; the amino acid at position 179 is G or deleted.; and
  • X at position 164 is selected from the group consisting of S, V, W, A, C, F, G, I, L, M and P; b) TOR beta chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 7, a CDR2 having the amino acid sequence of SEQ ID NO: 8 and a CDR3 having the amino acid sequence of SEQ ID NO: 9.
  • Item 16 A method of preparing a library of synthetic polynucleotides encoding a plurality of encoding TCR alpha chain constant regions and TCR beta chain constant regions, the method comprising:
  • Item 17 A kit comprising the library as defined in items 1 to 9, 14 or 15.
  • Item 18 The nucleotide sequences of the synthetic polynucleotides defined in items 1 to 4 in computer readable format.
  • Item 19 The amino acid sequences defined in items 1 to 4 in computer readable format.
  • TCR capable of binding to a PRAME peptide having the sequence VLDGLDVLL (SEQ ID NO: 3), wherein the TCR comprises:
  • TCR alpha chain comprising a) TCR alpha chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 4, a CDR2 having the amino acid sequence of SEQ ID NO: 5 and a CDR3 having the amino acid sequence of SEQ ID NO: 6; b) a constant TCR alpha region comprising the sequence selected from the group of constant TCR alpha regions represented by the sequence as set in SEQ ID NO 1 :
  • TCR beta chain comprising a) TCR beta chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 7, a CDR2 having the amino acid sequence of SEQ ID NO: 8 and a CDR3 having the amino acid sequence of SEQ ID NO: 9; b) a constant TCR beta region comprising the sequence selected from the group of constant TCR beta regions represented by the sequence as set in SEQ ID NO: 15, or a constant TCR beta region comprising the sequence selected from the group of constant TCR beta regions represented by the sequence as set in SEQ ID NO: 16.
  • Item 21 TCR according to item 20, wherein the TCR shows elevated expression levels of the heterologous TCR compared to wild type.
  • Item 22 TCR according to items 20 and 21 , wherein the TCR shows elevated activation levels compared to wild type.
  • Item 23 TCR according to items 20 to 22, wherein at in least one of X01 to X14 the amino acid is not the amino acid which occurs naturally in wild type at the respective position.
  • Item 24 The TCR according to items 20 to 23, wherein in at least two, at least three, at least four, at least five, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11 , at least 12, at least 13, such as in 14 positions of X01 to X14, the amino acid is not the amino acid which occurs naturally in wild type at the respective position.
  • TCR capable of binding to a PRAME peptide having the sequence VLDGLDVLL (SEQ ID NO: 3), wherein the TCR comprises:
  • TCR alpha chain comprising a) a variable TCR alpha chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 4, a CDR2 having the amino acid sequence of SEQ ID NO: 5 and a CDR3 having the amino acid sequence of SEQ ID NO: 6; b) A constant TCR alpha region comprising the sequence SEQ ID NO: 12
  • TCR beta chain comprising a) a variable TCR beta chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 7, a CDR2 having the amino acid sequence of SEQ ID NO: 8 and a CDR3 having the amino acid sequence of SEQ ID NO: 9; b) a constant TCR beta region comprising the sequence SEQ ID NO: 13; Item 26.
  • TCR according to items 19 to 25 , wherein the TCR specifically recognizes the amino acid sequence of SEQ ID NO: 3, which is presented by a molecule encoded by an HLA-A*02 gene.
  • TCR according to any one of items 19 to 23, wherein the TCR comprises a) a variable TCR a region having an amino acid sequence which is at least 80% identical to SEQ ID NO: 10 and b) a variable TCR [3 region having an amino acid sequence which is at least 80% identical to SEQ ID NO: 11 .
  • TCR according to any one of items 19 to 24, wherein the TCR comprises a variable TCR a region having the amino acid sequence of SEQ ID NO: 10 and a variable TCR [3 region having the amino acid sequence of SEQ ID NO: 11 .
  • Item 29 Nucleic acid encoding a TCR according to any one of items 19 to 28.
  • Item 30 Vector comprising the nucleic acid of item 29.
  • Item 31 Vector according to item 30, wherein the vector is an expression vector.
  • Item 32 Vector according to item 30 or 31 , wherein the vector is a retroviral vector.
  • Item 33 Vector according to item 30 or 31 , wherein the vector is a lentiviral vector.
  • Item 34 Cell expressing the TCR according to items 19 to 28, the nucleic acid according to item 27, the vector according to items 30 to 33.
  • Item 35 Cell according to item 34, wherein the cell is isolated or non-naturally occurring.
  • Item 36 Cell according to items 34 or 35, wherein the cell comprises the nucleic acid according to item 29 or the vector according to items 30 to 33.
  • Item 37 Cell according to items 34 to 36, wherein the cell comprises: a) an expression vector which comprises at least one nucleic acid as embodied in item 29, or b) a first expression vector which comprises a nucleic acid encoding the alpha chain of the TCR as embodied in any one of the items 20 to 28, and a second expression vector which comprises a nucleic acid encoding the beta chain of a TCR as embodied in any one of the items 20 to 28.
  • Item 38 Cell according to any one of items 34 to 37, wherein the cell is a peripheral blood lymphocyte (PBL) or a peripheral blood mononuclear cell (PBMC).
  • PBL peripheral blood lymphocyte
  • PBMC peripheral blood mononuclear cell
  • Item 39 Cell according to any one of items 34 to 38, wherein the cell is a T cell.
  • Item 40 Pharmaceutical composition comprising the TCR according to items 20 to 28, the nucleic acid according to item 29, the vector according to items 30 to 33, the cell according to any one of items 34 to 39.
  • Item 41 Pharmaceutical composition according to item 40 wherein the pharmaceutical composition comprises at least one pharmaceutically acceptable carrier.
  • Item 42 The TCR according to items 20 to 28, the nucleic acid according to item 29, the vector according to items 30 to 33, the cell according to any one of items 34 to 39 for use as a medicament.
  • Item 43 The TCR according to items 20 to 28, the nucleic acid according to item 27, the vector according to items 30 to 33, the cell according to any one of items 34 to 39 for use in the treatment of cancer.
  • Item 44 The TCR, the polypeptide, the multivalent TCR complex, the nucleic acid, the vector or the cell for use according to item 43, wherein the cancer is a hematological cancer or a solid tumor.
  • Item 45 The TCR, the polypeptide, the multivalent TCR complex, the nucleic acid, the vector or the cell for use according to item 44, wherein the cancer is a hematological cancer.
  • Item 46 The TCR, the polypeptide, the multivalent TCR complex, the nucleic acid, the vector or the cell for use according to item 45, Wherein the hematological cancer is Acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and multiple myeloma (MM).
  • AML Acute myeloid leukemia
  • MDS myelodysplastic syndromes
  • MM multiple myeloma
  • Item 47 The TCR, the polypeptide, the multivalent TCR complex, the nucleic acid, the vector or the cell for use according to item 43, wherein the cancer is a solid tumor.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une bibliothèque de polynucléotides synthétiques codant pour des régions constantes de chaîne TCR alpha et des régions constantes de chaîne TCR bêta d'un TCR capable de se lier à un peptide PRAME ayant la séquence VLDGLDVLL (SEQ ID NO : 3) pour l'appariement amélioré de chaînes TCR alpha et TCR bêta de recombinaison et/ou l'expression de surface améliorée de TCR de recombinaison. L'invention concerne en outre des bibliothèques de vecteurs, des bibliothèques de TCR, des bibliothèques de cellules et des procédés correspondants pour isoler des TCR ayant un appariement de chaînes TCR alpha et TCR bêta amélioré à l'aide desdites bibliothèques et de TCR isolés à partir desdites bibliothèques ainsi que leur utilisation médicale.
PCT/EP2023/056737 2022-03-16 2023-03-16 Bibliothèque d'appariement de régions constantes de tcr pour tcr pramevld WO2023175069A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22162442.2 2022-03-16
EP22162442 2022-03-16

Publications (1)

Publication Number Publication Date
WO2023175069A1 true WO2023175069A1 (fr) 2023-09-21

Family

ID=80784986

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/056737 WO2023175069A1 (fr) 2022-03-16 2023-03-16 Bibliothèque d'appariement de régions constantes de tcr pour tcr pramevld

Country Status (1)

Country Link
WO (1) WO2023175069A1 (fr)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007017201A1 (fr) 2005-08-05 2007-02-15 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh Production de cellules specifiques d'antigenes
EP2173869A2 (fr) 2007-06-21 2010-04-14 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Protéine de fusion comportant un domaine de caspase et un domaine associé au récepteur d'hormone nucléaire et procédés et utilisations associés
WO2017216324A1 (fr) 2016-06-17 2017-12-21 Medigene Immunotherapies Gmbh Récepteurs de lymphocytes t et leurs utilisations
WO2018104438A1 (fr) * 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant
WO2019232503A1 (fr) * 2018-06-01 2019-12-05 University Of Southern California Domaines divers de liaison à l'antigène, nouvelles plateformes et autres améliorations pour la thérapie cellulaire
KR20200036719A (ko) * 2018-09-28 2020-04-07 스미토모 고무 코교 카부시키카이샤 골프공
WO2020154617A1 (fr) * 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions et procédés de ciblage de ras mutants
WO2020172332A1 (fr) * 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Protéines de liaison spécifiques pour des néo-antigènes ras et leurs utilisations
WO2021099360A1 (fr) * 2019-11-18 2021-05-27 Medigene Immunotherapies Gmbh Récepteurs de prame tcr et utilisations correspondantes

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007017201A1 (fr) 2005-08-05 2007-02-15 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh Production de cellules specifiques d'antigenes
EP2173869A2 (fr) 2007-06-21 2010-04-14 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Protéine de fusion comportant un domaine de caspase et un domaine associé au récepteur d'hormone nucléaire et procédés et utilisations associés
WO2017216324A1 (fr) 2016-06-17 2017-12-21 Medigene Immunotherapies Gmbh Récepteurs de lymphocytes t et leurs utilisations
WO2018104438A1 (fr) * 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant
WO2019232503A1 (fr) * 2018-06-01 2019-12-05 University Of Southern California Domaines divers de liaison à l'antigène, nouvelles plateformes et autres améliorations pour la thérapie cellulaire
KR20200036719A (ko) * 2018-09-28 2020-04-07 스미토모 고무 코교 카부시키카이샤 골프공
WO2020154617A1 (fr) * 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions et procédés de ciblage de ras mutants
WO2020172332A1 (fr) * 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Protéines de liaison spécifiques pour des néo-antigènes ras et leurs utilisations
WO2021099360A1 (fr) * 2019-11-18 2021-05-27 Medigene Immunotherapies Gmbh Récepteurs de prame tcr et utilisations correspondantes

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BETHUNE, ELIFE, 2016
COHEN, CANCER RES., 2007
CRIBBS: "simplified production and concentration of lentiviral vectors to achieve high transduction in primary human T cells", BMC BIOTECHNOL, vol. 13, 2013, pages 98, XP021167925, DOI: 10.1186/1472-6750-13-98
ENGELS ET AL.: "Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity", CANCER CELL, vol. 23, no. 4, 2013, pages 516 - 26, XP028578787, DOI: 10.1016/j.ccr.2013.03.018
HAGA-FRIEDMAN, J IMMUNOL, 2012
KIEBACK ET AL., PROC NATL ACAD SCI USA., vol. 105, no. 2, 15 January 2008 (2008-01-15), pages 623 - 8
KUBALL, J EXP MED, 2009
SARAH MATKO ET AL: "PRAME peptide-specific CD8+ T cells represent the predominant response against leukemia-associated antigens in healthy individuals", EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY-VCH, HOBOKEN, USA, vol. 48, no. 8, 8 July 2018 (2018-07-08), pages 1400 - 1411, XP071227933, ISSN: 0014-2980, DOI: 10.1002/EJI.201747399 *
SOMMERMAYERUCKERT, J IMMUNOL, 2010
SPEAR TT ET AL: "TCR modifications that enhance chain pairing in gene-modified T cells can augment cross-reactivity and alleviate CD8 dependence", JOURNAL OF LEUKOCYTE BIOLOGY, JOHN WILEY & SONS LTD, GB, vol. Early View, Version of Record online: 19 JAN 2018, 19 January 2018 (2018-01-19), pages 1 - 11, XP009504174, ISSN: 0741-5400, DOI: 10.1002/JLB.5A0817-314R *
TANNO HIDETAKA ET AL: "Determinants governing T cell receptor [alpha]/[beta]-chain pairing in repertoire formation of identical twins", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 117, no. 1, 26 December 2019 (2019-12-26), pages 532 - 540, XP055937052, ISSN: 0027-8424, DOI: 10.1073/pnas.1915008117 *
THOMPSON ET AL., NUCL ACIDS RES, vol. 22, 1994, pages 4673 - 4680
USER'S MANUAL, 2004, pages 389 - 662
WILDE ET AL.: "Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity", BLOOD, vol. 114, no. 10, 2009, pages 2131 - 9, XP055848525, DOI: 10.1182/blood-2009-03-209387

Similar Documents

Publication Publication Date Title
EP3555124B1 (fr) Tcr nyeso
KR20210150440A (ko) Mage a4 t 세포 수용체
US20230037552A1 (en) MAGEA1 Specific T Cell Receptors and Their Use
US20230340064A1 (en) Mage-a3 specific t cell receptors and their use
AU2020309758B2 (en) Magea10 specific T cell receptors and their use
WO2023175069A1 (fr) Bibliothèque d'appariement de régions constantes de tcr pour tcr pramevld
WO2024041761A1 (fr) Combinaison de récepteurs de lymphocytes t spécifiques de ny-eso-1 et de récepteurs chimériques de costimulation
WO2023025779A1 (fr) Combinaison de récepteurs de lymphocytes t spécifiques antigène et de récepteurs co-stimulateurs chimériques
WO2022234116A1 (fr) Combinaison de récepteurs de lymphocytes t spécifiques de prame et de récepteurs co-stimulateurs chimériques
CN117915941A (zh) 抗原特异性t细胞受体与嵌合共刺激受体的组合
JP2021532814A (ja) Ｈａ−１特異的ｔ細胞受容体およびその使用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23711475

Country of ref document: EP

Kind code of ref document: A1